A Study to Evaluate the Efficacy and Safety of RNK08954 in Subjects With KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Latest Information Update: 01 Jan 2026
At a glance
- Drugs RNK 08954 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Ranok Therapeutics
Most Recent Events
- 01 Jan 2026 New trial record